Abstract: The present invention relates to compounds derived from deoxy fucose. These compounds are useful as lectin inhibitors, especially as inhibitors of LecB. The invention also relates to pharmaceutical compositions comprising these compounds. The invention further relates to therapeutic uses of these compounds, especially to the prophylaxis or treatment of infections involving Pseudomonas aeruginosa.

Abstract: The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g.

Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

Abstract: In a first aspect, the present invention relates to a method for screening bacteria on their susceptibility against candidate compounds. In a further aspect, the present invention relates to a method for screening the antibiotic efficacy of candidate compounds suppose to have an antibiotic activity on bacteria. Moreover, the present invention relates to a method for forming a bacterial biofilm on a support, a system allowing in vitro and in vivo evaluation of biofilms formed by bacteria as well as methods for the stratification of the treatment regimen against bacterial infections.

Abstract: A method for determination of the growth rate of biofilm (7) using an electrical impedance analyses is disclosed. The method comprises the steps of: bringing a culture medium fluid (3) in contact to an electrode structure (4a, 4b), having biofilm (7) grown within the fluid culture medium (3) with the biofilm (7) arranged in distance to the electrodes structure (4a, 4b), so that the fluid culture medium (3) is placed between the growing biofilm (7) and the electrode structure (4a, 4b); measuring the impedance of the electrodes structure (4a, 4b) over a monitoring time, and determining the growth rate of the biofilm (7) as a function of the reduction rate of the impedance values measured on the electrode structure (4a, 4b).

Abstract: The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.

Abstract: The present invention relates to a carrier system, a carrier and a pharmaceutical composition comprising a pathogen entry protein or fragment thereof, which specifically binds to a molecule on the surface of a mammalian target cell of said pathogen and which is covalently linked to the surface of said carrier and at least one hydrophilic antipathogenic agent. It further relates to a method of manufacturing a carrier system and the carrier system or the pharmaceutical composition for the use as a medicament.

Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.

Abstract: The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.

Abstract: The invention provides the amino acid sequences comprised in or constituting the synthetic pathway enzymes participating in the production of Argyrins, as well as the nucleic acid sequences encoding the synthetic pathway enzymes participating in the production of Argyrins, as well as genetically manipulated microorganisms containing nucleic acid sequences encoding the synthetic pathway enzymes for the production of Argyrins, e.g. for inserting one or more of these coding sequences, mutating in a targeted manner one or more of these nucleic acid sequences, in a wild type producer micro-organism or in a heterologous micro-organism, for the production of Argyrins.

Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

Abstract: The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

Abstract: The present invention relates to a streptococcal octapeptide AXYLXXLN, and preferably to the octapeptide AXYLZZLN, designated as peptide associated with rheumatic fever (PARF) that, through its interaction with human collagen, plays a crucial role in the pathogenesis of rheumatic fever. PARF therefore represents a marker for rheumatic fever associated strains and provides a target for therapies, and in particular preventive therapies.

Abstract: The present invention relates to an improved method for the synthesis of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof.

Abstract: The invention provides a compound termed Carolacton having the structure and derivatives thereof for medical use against biofilm formation by bacteria.

Abstract: The present invention describes new compounds (e.g.

Abstract: The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

Abstract: There are described tooth filling materials and dental varnishes for inhibiting the biofilm formation of Streptococcus mutans containing (a) a quantity of an active substance for inhibiting the biofilm formation, (b) a material for forming a structure for the uptake and delayed release of the active substance and (c) a filling material system. Another aspect of this invention relates to a method for producing tooth filling materials or dental varnishes according to the invention for inhibiting the biofilm formation of Streptococcus mutans. The present invention also relates to a kit comprising tooth filling materials or dental varnishes according to the invention and one or more additional constituents. There are also described methods for inhibiting the biofilm formation of Streptococcus mutans, methods for producing a dental component which inhibits the biofilm formation and the use of the active substance for producing a dental material.

Abstract: The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting Streptococcus strains of the anginosus group, preferably for detecting Streptococcus anginosus and/or Streptococcus constellatus as well as for discriminating Streptococcus anginosus and/or Streptococcus constellatus from other streptococci. The present invention furthermore relates to these nucleic acids and polypeptides for use in the diagnosis and/or prognosis of infections with Streptococcus strains of the anginosus group. The present invention furthermore relates to methods utilizing these nucleic acids and polypeptides as well as to arrays and antibodies.

Abstract: The present invention relates to a method for the preparation of a therapeutical composition, in particular, the present invention relates to a method for treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll like receptor 2 and/or TLR 6 agonist and using these pretreated dendritic cells for the preparation of a therapeutical composition. Moreover, the present invention relates to a therapeutical composition containing dendritic cells and the use thereof for the treatment of various diseases and disorders.